Indica Labs and Ibex Medical Analytics have announced an agreement to integrate the Galen AI-based cancer diagnostics platform into the HALO AP digital pathology workflow platform.
The HALO AP platform was developed by Indica Labs to address the needs of digital anatomical pathology laboratories. The platform can be fully integrated within existing LIS or HIS solutions or can operate as a standalone case and image management system. Furthermore, HALO AP supports a full range of tissue-based assays and workflows, including synoptic reporting, tumour boards, secondary consultations, quantitative analysis, and AI-assisted workflows. HALO AP is used by some of the largest anatomical pathology laboratories in the world, including NeoGenomics and the National Cancer Institute (NCI).
Ibex’s Galen platform uses strong-AI algorithms that support pathologists in improving the quality of cancer diagnosis and providing productivity-enhancing insights that help reduce turnaround times. Installed in laboratories worldwide and used as part of everyday clinical practice, Galen routinely detects misdiagnosed and misgraded cancers in digitised slides, guiding pathologists to areas of cancer in support of a prompt review. In recent clinical studies, the Galen platform demonstrated outstanding clinical outcomes, including the highest accuracy levels reported in the field for prostate cancer, one- to two-day reductions in total turnaround time, and 37% productivity gain for pathologists, compared to conventional microscope viewing.
The integration between HALO AP and the Galen platform is designed to enable a seamless experience for the end-user. Galen adds AI-powered cancer detection, case prioritisation, grading and other productivity-enhancing insights displayed directly within the HALO AP platform, so there is no need to use a separate viewer. Where applicable, the data will be communicated with the LIS or HIS system automatically.
